Results 151 to 160 of about 5,478,695 (241)

An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cells

Journal for ImmunoTherapy of Cancer
Background To accelerate the translation of novel immunotherapeutic treatment approaches, the development of analytic methods to assess their efficacy at early in vitro stages is necessary. Using a droplet-based microfluidic platform, we have established a method for multiparameter quantifiable phenotypic and ...
Matthew Ryan Sullivan, Michael Finocchiaro, Yichao Yang, Judene Thomas, Alaa Ali, Isabel Kaplan, Yasmin Abdulhamid, Eden Bobilev, Michal Sheffer, Rizwan Romee, Tania Konry   +10 more
openaire   +3 more sources

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick, Margaretha A. Skowron, Gereon Poschmann, Patrick Petzsch, Ann Kathrin Bergmann, Kai Stühler, Jochen Hecht, Daniel Nettersheim   +7 more
wiley   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside

Molecular Cancer
Background Gastrointestinal (GI) cancers represent a significant health burden worldwide. Their incidence continues to increase, and their management remains a clinical challenge.
Xingwang Zhu, Jieyun Xue, Hongzhou Jiang, Dongwei Xue   +3 more
doaj   +1 more source

Cord blood-derived natural killer cells engineered with a novel, highaffinity chimeric antigen receptor can eliminate acute myeloid leukemia cells with minimal C-type lectin-like molecule-1 expression

Haematologica
CAR NK cell therapy is expected to be developed to treat acute myeloid leukemia (AML). C-type lectin-like molecule 1 (CLL-1) is a candidate target. However, AML cells with minimal CLL-1 expression (CLL-1dim) may not be eliminated by CAR NK cells.
Makiko Suga, Shuhei Kida, Yo Mizutani, Yosuke Kogue, Yuta Yamaguchi, Shunya Ikeda, Ryuhei Kawamoto, Mana Tachikawa, Tsubasa Seto, Hiroto Takekawa, Yuto Maehara, Kumi Shibata, Kazuhito Tsutsumi, Hiraku Murakami, Emiko Mizuta, Kyoko Yoshihara, Satoshi Yoshihara, Hirohisa Nakamae, Takafumi Nakao, Megumu Inoue, Shuji Ueda, Satoru Kosugi, Yasutaka Ueda, Hisashi Kato, Shinsuke Kusakabe, Hidenori Kasahara, Akihisa Hino, Jiro Fujita, Tomoaki Ueda, Michiko Ichii, Kentaro Fukushima, Naoki Hosen   +31 more
doaj   +1 more source

Genetic Engineering of Tumor‐Infiltrating Lymphocytes (TIL) via a T‐Editor Platform to Enhance Anti‐Tumor Activity

Cancer Science, EarlyView.
A rapid and efficient CRISPR‐mediated gene editing platform for TIL engineering identified FAM84B as a novel potential target to enhance antitumor activity and pioneered the use of CBE to generate FAM84B loss‐of‐function TIL with enhanced antitumor activity.
Fenge Li, Xuejiao Ma, Yongming Xue, Jilong Yang, Ruijing Wang, Xiang Li, Chao Zhang, Wenhan Lu, Mei Liu, Yue Xu, Xinyi Wang, Shengnan Wu, Ning Kang, Chunhua Ma   +13 more
wiley   +1 more source

Cord Blood‐Derived Fibroblast Activation Protein‐Targeted Chimeric Antigen Receptor Natural Killer Cells Persist in Vivo

Cancer Science, EarlyView.
We generated cord blood‐derived FAP‐targeted CAR NK cells and evaluated their activity against cancer‐associated fibroblasts. These cells showed antigen‐specific cytotoxicity in vitro and robust persistence in a pleural dissemination model, although in vivo anti‐CAF efficacy was limited, supporting further development of stromal‐targeted cellular ...
Takashi Hiroshima, Toru Kimura, Mariko Maekawa, Mayuko Noguchi, Takahiro Matsui, Shunya Ikeda, Makiko Suga, Hideki Nagata, Kenji Kimura, Eriko Fukui, Takashi Kanou, Naoko Ose, Eiichi Morii, Yasushi Shintani, Naoki Hosen   +14 more
wiley   +1 more source

Advances in the Role of Chemokines in Microwave Ablation‐Based Combinatorial Immunotherapy

Cancer Science, EarlyView.
MWA can initiate antitumor immunity through tumor antigen release and innate immune activation, but iMWA may instead promote an immunosuppressive microenvironment. Combining MWA with immunotherapeutic strategies offers a promising approach to enhance systemic immunity and suppress residual and distant tumors.
Ruijie An, Ningning He, Wendong Gu
wiley   +1 more source